Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT
- Conditions
- Myelodysplastic SyndromeAllogeneic Hematopoietic Stem Cell TransplantationConditioning
- Interventions
- Drug: Granulocyte Colony-Stimulating Factor(G-CSF)
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 242
- Registration Number
- NCT05453552
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT
- Conditions
- ConditioningSecondary Acute Myeloid Leukemia Evolving From MDSAllogeneic Hematopoietic Stem Cell Transplantation
- Interventions
- Drug: Granulocyte Colony-Stimulating Factor(G-CSF)
- First Posted Date
- 2022-07-08
- Last Posted Date
- 2022-07-08
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 232
- Registration Number
- NCT05449899
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- Conditions
- Hematologic Neoplasms
- Interventions
- Procedure: donor lymphocyte infusion
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 430
- Registration Number
- NCT05327023
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
- Conditions
- Neuroblastoma
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2022-07-01
- Target Recruit Count
- 64
- Registration Number
- NCT05303727
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
- Conditions
- Stem Cell Transplantation
- Interventions
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05293509
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
- Conditions
- T-lymphoblastic LymphomaAcute Biphenotypic LeukemiaAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaAcute LeukemiaAcute Undifferentiated LeukemiaMyelodysplastic Syndromes
- Interventions
- Radiation: Total Body IrradiationProcedure: Bone Marrow Transplant
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Ossium Health, Inc.
- Registration Number
- NCT05170828
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
- Conditions
- ImmunodeficiencyHematopoietic Stem Cell Transplantation
- Interventions
- Procedure: Allogeneic HSCTRadiation: Total Body Irradiation (TBI)
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 54
- Registration Number
- NCT05027945
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biological: CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Guenther Koehne
- Target Recruit Count
- 20
- Registration Number
- NCT04982354
- Locations
- 🇺🇸
Miami Cancer Institute at Baptist Health of South Florida, Miami, Florida, United States
Outcomes of Patients After Allo-HSCT With Decitabine and NAC
- Conditions
- Engraft FailureRelapseGVHD
- Interventions
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 100
- Registration Number
- NCT04945096
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)
- Conditions
- Leukemia, Acute LymphoblasticMyeloid Leukemia, AcuteMyelodysplastic SyndromesMyeloproliferative NeoplasmLymphoblastic LymphomaBiphenotypic Acute Leukemia
- Interventions
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 50
- Registration Number
- NCT04942730
- Locations
- 🇷🇺
RM Gorbacheva Research Institute, Saint Petersburg, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.